Novel Potassium Binders for Hyperkalemia and Optimization of RAAS Inhibitor Therapy in CKD or Heart Failure: A Systematic Review and Meta-analysis
Newer potassium-lowering medicines helped patients stay on full doses of heart- and kidney-protective RAAS-inhibitor drugs by controlling high potassium, with the biggest benefit in chronic kidney disease.
Background
RAAS inhibitors are essential in CKD and heart failure, but hyperkalemia often forces dose reduction or discontinuation, undermining cardiovascular and renal protection. This review evaluated hyperkalemia incidence on RAASi and the efficacy of novel potassium binders in enabling RAASi optimization.
Key findings
Across 83 studies (part 1) the pooled hyperkalemia incidence on RAASi was 10.7%, rising to 24.4% with ACEi/ARB/ARNi plus MRA combinations. In 8 RCTs (part 2), novel potassium binders improved RAASi optimization by 38% (RR 1.38, 95% CI 1.16-1.65), reduced hyperkalemia by 28%, and lowered potassium by 0.71 mEq/L.
Clinical implications
Novel potassium binders can help patients remain on protective RAASi therapy despite hyperkalemia risk, with the CKD population deriving substantially greater optimization benefit (84%) than the heart failure population (29%).
Category
Research
Source
Drugs
More from ASNRT News
Browse the latest news, society announcements, KDIGO guideline updates, and AJNT issue releases on the ASNRT newsroom.